Knuff & Co LLC boosted its position in shares of Moderna by 5.4% during the 3rd ... and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus ...

The most impactful development was the rapid success of Moderna's COVID-19 vaccine, Spikevax, which witnessed massive demand during the pandemic. Starting in early 2021, regulatory approvals from ...

In December 2020, both Moderna's Spikevax and Pfizer / BioNTech's Comirnaty COVID vaccines received emergency use authorization (“EUA”) in the US. Both used a pioneering new mechanism of ...

A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ ... best known as the producer of the Spikevax COVID vaccine, pushed its stock nearly 16% higher during ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Pfizer and BioNTech earned more than $3.3 billion in revenue from global sales of their vaccine Comirnaty last year, while Moderna earned $3.2 billion from its vaccine Spikevax, according to ...

Moderna collected $3.1 billion in 2024 Spikevax sales and $25 million from its newer mRESVIA. At its peak in 2022, Spikevax brought in $18.4 billion for the company.

Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax® and, where applicable, additional Moderna products that Moderna has represented use the same LNP technology ...

Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax ® and, where applicable, additional Moderna products that Moderna has represented use the same LNP technology, ...